TOKYO, Japan — December 23, 2025 — The Japanese Ministry of Health, Labour and Welfare (MHLW) has granted approval for Dupixent (dupilumab) for the treatment of children aged 6 to 11 years with bronchial asthma, marking a significant pediatric label expansion in one of the world’s most tightly regulated pharmaceutical markets. The decision expands prior authorization limited to patients aged 12 years and older and reflects growing confidence in targeted biologic therapies for pediatric respiratory disease, supported by robust global Phase III clinical evidence.
Science Significance
From a scientific standpoint, the approval reinforces the role of type 2 inflammation as a central driver of pediatric asthma pathology and validates IL-4 and IL-13 pathway inhibition as an effective disease-modifying strategy. Dupixent is a fully human monoclonal antibody that selectively blocks IL-4 and IL-13 signaling, reducing airway inflammation without broadly suppressing the immune system. Clinical data from the global VOYAGE Phase III trial demonstrated that Dupixent reduced severe asthma exacerbations by 54% to 65% and significantly improved lung function in children aged 6 to 11 years. Importantly, Dupixent is the first biologic to show lung function improvement in this age group in a randomized Phase III study, underscoring its differentiated scientific profile.
Regulatory Significance
Regulatorily, the MHLW decision highlights Japan’s alignment with global pediatric development standards and acceptance of multinational clinical data complemented by local population evidence. The approval was supported not only by VOYAGE but also by the EXCURSION open-label extension study, which included a dedicated Japanese pediatric cohort. This reflects regulatory confidence in extrapolating global efficacy and safety findings while ensuring relevance to domestic patients. The approval also signals increasing regulatory willingness to expand biologic indications into younger pediatric populations, provided long-term safety and efficacy are well characterized.
Business Significance
Advertisement
From a commercial perspective, the pediatric asthma approval strengthens Dupixent’s position as a multi-indication blockbuster biologic and further extends its lifecycle value in Asia. Japan represents a strategically important market with high standards for pricing, reimbursement, and post-marketing surveillance, making pediatric approval particularly impactful. The expansion broadens the eligible patient base and reinforces Dupixent’s standing as a foundational franchise therapy across allergic and inflammatory diseases. For its developers, Sanofi and Regeneron, the decision underscores the success of long-term investment in precision immunology platforms and coordinated global regulatory strategies.
Patients’ Significance
For pediatric patients and caregivers, the approval addresses a critical unmet medical need. Despite standard inhaled corticosteroids and bronchodilators, many children with asthma continue to experience frequent exacerbations, impaired lung growth, and reduced quality of life. Early lung function impairment can have lifelong consequences if not adequately treated. By providing access to a targeted biologic therapy, the approval offers children with severe or refractory asthma a chance for better disease control, fewer systemic corticosteroid exposures, and improved daily functioning, including school attendance and physical activity.
Policy Significance
At a policy level, the decision reflects broader healthcare priorities emphasizing early intervention, precision medicine, and reduction of long-term disease burden in pediatric populations. Asthma remains one of the most common chronic childhood diseases, with significant economic and social costs. Supporting access to evidence-based biologics aligns with policy goals of preventing disease progression, reducing hospitalizations, and minimizing reliance on systemic steroids. The approval also contributes to international regulatory harmonization, reinforcing Japan’s role as a key ICH market adopting globally validated therapies for vulnerable populations.
The approval of Dupixent for children aged 6 to 11 years with bronchial asthma in Japan marks a major milestone in pediatric respiratory care and highlights the maturation of targeted biologic therapies across age groups. By combining strong clinical evidence, regulatory rigor, and a clear patient benefit, the decision reinforces Dupixent’s role as a cornerstone therapy in type 2 inflammatory disease. For regulators, clinicians, and patients alike, this expansion represents meaningful progress toward earlier, more precise, and more effective asthma management.
Source: Regeneron Pharmaceuticals, Inc. press release
